10-Q quarterly report · filed Nov 12, 2026

Erasca, Inc. (ERAS) Q3 2026 10-Q Quarterly Report

Short answer

Erasca, Inc. (ERAS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$51M
−67.7% YoY · −16.5% QoQ
EPS (diluted)
−$0.13
−18.2% YoY · +7.1% QoQ

Source: XBRL data from the Erasca, Inc. (ERAS) Q3 2026 10-Q on SEC EDGAR. USD.

Erasca, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, reflecting no approved products or product sales
  • Net loss $51.3M vs $30.6M YoY, operating loss $59.5M vs $34.5M
  • ERAS-0015 strongest program, 57% uORR at 32 mg QD in 2L+ KRAS G12X PDAC
  • Cash, equivalents and marketable securities $947.8M, supported by $593.5M July offering
  • Operating cash outflow $87.4M vs $73.7M YoY, with $712.7M investing outflow and $845.2M financing inflow

Risk Factors

  • New IP infringement risk triggered by RevMed’s April 24, 2026 letter targeting ERAS-0015 and alleging patent infringement and trade-secret misappropriation
  • New securities litigation risk triggered by June 10, 2026 class action and August 2026 derivative complaint
  • Regulatory and compliance risk: RevMed alleges improper comparative preclinical disclosures involving ERAS-0015 and RMC-6236
  • Operational risk: potential injunctions could delay or prevent ERAS-0015 development and commercialization
  • Financial risk: litigation could produce substantial legal fees, monetary damages, settlements, fines, or penalties

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Erasca, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.